WATERTOWN, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today reported financial results for its fiscal 2017 third quarter and nine months ended March 31, 2017. The Company’s progress during the third quarter has set the stage for the achievement of several near-term goals during the remainder of calendar 2017 including:
Durasert™ Three-Year for Posterior Segment Uveitis:
